Prescriber's Corner
Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
Patrick J. Fleming Jr., PharmD, BCOP, Sylvia Karpio, PharmD candidate, and Nicholas Lombardo, PharmD candidate
From University of Illinois at Chicago, Chicago, Illinois
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Patrick J. Fleming Jr., PharmD, BCOP, University of Illinois at Chicago, 840 S Wood St., Chicago, IL 60607.
E-mail: pflemi2@uic.edu
J Adv Pract Oncol 2021;12(7):747–752 |
https://doi.org/10.6004/jadpro.2021.12.7.8 |
© 2021 Harborside™
ABSTRACT
Sacituzumab govitecan was initially approved in April 2020 under accelerated approval for the treatment of patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. A confirmatory phase III trial evaluating sacituzumab govitecan vs. chemotherapy of the provider’s choice was published in April 2021. Based on this trial, the FDA granted sacituzumab govitecan full regulatory approval. This antibody-drug conjugate is composed of a monoclonal antibody targeted at Trop-2 and contains the active metabolite of irinotecan, SN-38, as a cytotoxic side moiety. In a phase III clinical trial, sacituzumab govitecan demonstrated a median progression-free survival of 5.7 months vs. 1.7 months with chemotherapy. It is now an additional option for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
For access to the full length article, please
sign in.
